相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
Matthew A. Cavender et al.
CIRCULATION (2015)
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist
Tian-Quan Cai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Giulia Magnani et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
William Schuyler Jones et al.
AMERICAN HEART JOURNAL (2014)
Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
Marco Valgimigli et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery
David J. Whellan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Coronary Stent Thrombosis With Vorapaxar Versus Placebo Results From the TRA 2°P-TIMI 50 Trial
Marc P. Bonaca et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Vorapaxar in Patients With Peripheral Artery Disease Results From TRA2°P-TIMI 50
Marc P. Bonaca et al.
CIRCULATION (2013)
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial
Sergio Leonardi et al.
EUROPEAN HEART JOURNAL (2013)
The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar
Teddy Kosoglou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations)
Jeffrey L. Anderson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke
David A. Morrow et al.
STROKE (2013)
The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects
Martin O. Behm et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
Teddy Kosoglou et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment
Paul Statkevich et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
Teddy Kosoglou et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
Benjamin M. Scirica et al.
LANCET (2012)
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist
Anima Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2011)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects
Samuel Chackalamannil
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Protease-activated receptors in cardiovascular diseases
Andrew J. Leger et al.
CIRCULATION (2006)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
DL Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
ZM Chen et al.
LANCET (2005)
Protease-activated receptors in hemostasis, thrombosis and vascular biology
SR Coughlin
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
